热门资讯> 正文
KalVista Pharmaceuticals GAAP每股收益为-0.87美元，击败0.11美元
2024-09-05 18:34
- KalVista Pharmaceticals press release (NASDAQ:KALV): Q1 GAAP EPS of -$0.87 beats by $0.11.
- Cash, cash equivalents and marketable securities were $174.3 million on July 31, 2024, compared to $210.4 million on April 30, 2024. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.
More on KalVista Pharmaceticals
- Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch
- Seeking Alpha’s Quant Rating on KalVista Pharmaceticals
- Historical earnings data for KalVista Pharmaceticals
- Financial information for KalVista Pharmaceticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
